My research project has been focused on the technical development of a targeted next-generation sequencing panel to evaluate clonal hematopoiesis (CH) mutations in rare cellular populations and in patients with solid tumor malignancies. Using this panel, we will also study the response to checkpoint blockade in patients harboring CH variants and determine the mechanism of progression from CH to cardiovascular or oncologic disease.